circles-27975_640.jpg

September 7, 2020by Richard Treanor

On July 14, 2020, the Patent Trial and Appeal Board issued a decision in Ex parte Park (Appeal 2019-006050) in which a rejection over an overlapping prior art genus was determined to be insufficient to establish a prima facie case of obviousness under both a lead compound analysis and an obvious equivalents/overlapping genus analysis. In addition, the Examiner’s initial rejection of subject matter beyond the elected specie was determined to be a withdrawal of the election requirement.


draw-serie-compass-rule-2-1241404.jpg

September 3, 2020by Mamoru Kakuda

2020年4月8日に米国CAFCは、クレームされた物質に関する数値範囲と引例に記載された類似物質に関する数値範囲とが重なる場合、prima facie case of obviousness と判断し得る、と判示しました(Valeant Pharmaceuticals Intl. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2020)) 。